Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial

  • End date
    Dec 7, 2024
  • participants needed
  • sponsor
    The George Institute
Updated on 7 September 2021
systolic blood pressure


An investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial to determine the effect of more intensive blood pressure control provided by a fixed low-dose combination blood pressure lowering pill ("Triple Pill") strategy on top of standard of care, on time to first occurrence of recurrent stroke in patients with a history of stroke due to intracerebral haemorrhage.


Intracerebral haemorrhage (ICH) is the most serious and least treatable form of stroke, accounting for at least 10% of the 20 million new strokes that occur globally each year. Survivors of ICH are at high risk of recurrent ICH and other serious cardiovascular events.

While there is strong evidence that this risk can be reduced by lowering the blood pressure (BP) of patients after ICH, many patients with ICH do not receive BP-lowering treatment long-term unless BP levels are particularly high, and many do not receive BP combination therapy.

The aim of this study is to assess the safety and efficacy of a combination of fixed low-dose generic BP lowering agents, as a "Triple Pill" strategy on top of standard of care for the prevention of recurrent stroke in patients with a history of ICH and high normal or low grade hypertension. The study is a large-scale, international, double-blind, placebo-controlled, randomised controlled trial.

Condition Hypertension, cerebral bleeding, arterial hypertension, intracerebral haemorrhage, High Blood Pressure (Hypertension), hemorrhage cerebral, intracerebral hemorrhage, High Blood Pressure (Hypertension - Pediatric), Cerebral Hemorrhage, Vascular Diseases, Diabetes and Hypertension, high blood pressure, Elevated Blood Pressure, Acute Intracerebral Haemorrhage (ICH), intracerebral hemorrhage (ich)
Treatment Placebo, telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg
Clinical Study IdentifierNCT02699645
SponsorThe George Institute
Last Modified on7 September 2021


Yes No Not Sure

Inclusion Criteria

Adults (18 years) with a history of up to 12 months after symptom onset of primary ICH that is confirmed by imaging (copy of the brain imaging report to be uploaded to the database, labelled with participant identification (ID) and with personal identifiers removed)
Clinically stable, as judged by investigator
Average of two resting SBP levels measured 5 minutes apart in the range 130-160mmHg recorded in a seated position (National Heart Foundation of Australia Guidelines). (Patients with higher SBP can be included if considered by attending clinician that management is consistent with local standards of clinical practice)
Geographical proximity to the recruiting hospital and/or follow-up medical clinic site to allow ready access for in-person clinic visits during follow-up
No clear contraindication to any of the study treatments
Provision of written informed consent

Exclusion Criteria

Taking an ACE-I that cannot be switched to any of the following alternatives
telmisartan 20 or 40mg, amlodipine 2.5 or 5mg, indapamide 1.25mg, or
an equivalent class (ARB, CCB or thiazide [TZ]-like diuretic), or
a BB
Contraindication to any of the study medications, in the context of currently prescribed BP-lowering medication
Unable to complete the study procedures and/or follow-up
Females of child-bearing age and capability, who are pregnant or breast-feeding, or those of child-bearing age and capability who are not using adequate birth control
Significant hyperkalaemia and/or hyponatremia, in the opinion of the responsible physician
Estimated glomerular filtration rate (eGFR) <30mL/min/1.73m2
Severe hepatic impairment (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >3x the upper limit of normal [ULN])
Any other condition that in the opinion of the responsible physician investigator renders the patient unsuitable for the study (e.g. severe disability [i.e. simplified modified Rankin Scale (smRS) of 4-5] or significant memory or behavioural disorder)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note